Gilead Sciences (GILD) Given a $86.00 Price Target by Raymond James Analysts

Raymond James set a $86.00 target price on Gilead Sciences (NASDAQ:GILD) in a research note published on Tuesday morning, Stock Target Advisor reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

GILD has been the topic of a number of other reports. ValuEngine cut Gilead Sciences from a hold rating to a sell rating in a research note on Wednesday, February 13th. Mizuho set a $88.00 target price on shares of Gilead Sciences and gave the stock a buy rating in a report on Friday, March 22nd. BidaskClub lowered shares of Gilead Sciences from a buy rating to a hold rating in a report on Thursday, February 7th. Wells Fargo & Co dropped their target price on shares of Gilead Sciences from $95.00 to $89.00 and set an outperform rating for the company in a report on Tuesday, February 5th. Finally, Oppenheimer upgraded shares of Gilead Sciences from a market perform rating to an outperform rating and set a $85.00 target price for the company in a report on Thursday, January 3rd. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and fourteen have given a buy rating to the company. The stock currently has an average rating of Buy and a consensus target price of $80.94.

Shares of NASDAQ:GILD opened at $64.14 on Tuesday. Gilead Sciences has a 12-month low of $60.32 and a 12-month high of $79.61. The stock has a market cap of $80.37 billion, a PE ratio of 10.43, a P/E/G ratio of 4.15 and a beta of 1.16. The company has a current ratio of 3.38, a quick ratio of 3.30 and a debt-to-equity ratio of 1.19.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Monday, February 4th. The biopharmaceutical company reported $1.44 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.70 by ($0.26). Gilead Sciences had a net margin of 24.65% and a return on equity of 37.03%. The company had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.52 billion. During the same period last year, the business posted $1.78 earnings per share. The firm’s quarterly revenue was down 2.6% compared to the same quarter last year. As a group, analysts anticipate that Gilead Sciences will post 6.3 EPS for the current year.

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 28th. Shareholders of record on Friday, March 15th were issued a $0.63 dividend. The ex-dividend date of this dividend was Thursday, March 14th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.57. This represents a $2.52 annualized dividend and a yield of 3.93%. Gilead Sciences’s dividend payout ratio (DPR) is 40.98%.

In other Gilead Sciences news, Director Richard James Whitley sold 9,534 shares of the firm’s stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $65.48, for a total value of $624,286.32. Following the completion of the sale, the director now directly owns 34,669 shares in the company, valued at $2,270,126.12. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director John Francis Cogan sold 2,700 shares of the firm’s stock in a transaction dated Wednesday, March 20th. The stock was sold at an average price of $65.07, for a total transaction of $175,689.00. Following the completion of the sale, the director now owns 57,560 shares of the company’s stock, valued at $3,745,429.20. The disclosure for this sale can be found here. Insiders sold 44,802 shares of company stock valued at $2,956,422 over the last 90 days. 0.20% of the stock is currently owned by company insiders.

A number of institutional investors and hedge funds have recently modified their holdings of GILD. Oregon Public Employees Retirement Fund lifted its holdings in Gilead Sciences by 5,733.7% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 28,988,297 shares of the biopharmaceutical company’s stock worth $463,000 after buying an additional 28,491,386 shares during the period. Norges Bank purchased a new stake in Gilead Sciences in the fourth quarter worth about $798,882,000. BlackRock Inc. lifted its holdings in Gilead Sciences by 2.2% in the fourth quarter. BlackRock Inc. now owns 104,186,077 shares of the biopharmaceutical company’s stock worth $6,516,839,000 after buying an additional 2,195,948 shares during the period. TIAA CREF Investment Management LLC lifted its holdings in Gilead Sciences by 21.1% in the third quarter. TIAA CREF Investment Management LLC now owns 10,241,394 shares of the biopharmaceutical company’s stock worth $790,738,000 after buying an additional 1,786,881 shares during the period. Finally, Vanguard Group Inc lifted its holdings in Gilead Sciences by 1.1% in the third quarter. Vanguard Group Inc now owns 97,167,329 shares of the biopharmaceutical company’s stock worth $7,502,290,000 after buying an additional 1,071,619 shares during the period. Institutional investors and hedge funds own 80.21% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. Its primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.

Further Reading: Calculating net profit and net profit margin ratio

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.